Shots:
- AstraZeneca to get exclusive promotion rights for toripalimab in mainland China for the urothelial carcinoma indications and all indications in non-core areas
- Junshi will continue responsible for the promotion of other approved indications and to be approved excluding urothelial carcinoma in core areas
- The companies will continue to explore overseas business collaborations including emerging markets and actively explore the possibility of expanding the future collaborations
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Fierce Pharma
The post AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China first appeared on PharmaShots.
